

# Dhruv S Kazi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6945982/dhruv-s-kazi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86

papers

2,251

citations

23

h-index

46

g-index

98

ext. papers

3,158

ext. citations

9.9

avg, IF

5.48

L-index

#	Paper	IF	Citations
86	Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry.. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022	5.8	1
85	Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure.. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, CIRCOUTCOMES121008443	5.8	1
84	A prospective cohort study examining exposure to incarceration and cardiovascular disease (Justice-Involved Individuals Cardiovascular Disease Epidemiology - JUSTICE study): a protocol paper.. <i>BMC Public Health</i> , 2022, 22, 331	4.1	
83	Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults.. <i>Journal of the American Heart Association</i> , 2022, e025192	6	0
82	Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1954-1964	15.1	2
81	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021, CIRCHEARTFAILURE121008477	7.6	0
80	Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice: Findings From EXTEND-CoreValve. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2112-2123	5	2
79	Characteristics of Populations Excluded From Clinical Trials Supporting Intensive Blood Pressure Control Guidelines. <i>Journal of the American Heart Association</i> , 2021, 10, e019707	6	3
78	Prognosis of Claims- Versus Trial-Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. <i>Journal of the American Heart Association</i> , 2021, 10, e018744	6	1
77	Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India. <i>Indian Heart Journal</i> , 2021, 73, 169-173	1.6	1
76	Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. <i>Heart</i> , 2021,	5.1	3
75	Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007521	5.8	2
74	Scaling Up Pharmacist-Led Blood Pressure Control Programs in Black Barbershops: Projected Population Health Impact and Value. <i>Circulation</i> , 2021, 143, 2406-2408	16.7	6
73	Addressing the Last-Mile Problem in Blood Pressure Control: Scaling Up Community-Based Interventions. <i>JAMA Health Forum</i> , 2021, 2, e212022	2	1
72	Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. <i>Circulation</i> , 2021, 143, 2384-2394	16.7	9
71	Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. <i>Circulation</i> , 2021, 143, 2346-2354	16.7	16
70	Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 273-279	4.6	3

69	Cardiovascular Deaths During the COVID-19 Pandemic in the United States. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 159-169	15.1	49
68	Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 445-453	27.4	7
67	Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004-17. <i>Health Affairs</i> , <b>2021</b> , 40, 289-296	7	6
66	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25690	5.4	1
65	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2114501	10.4	9
64	Establishment of a cardiac telehealth program to support cardiovascular diagnosis and care in a remote, resource-poor setting in Uganda. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255918	3.7	2
63	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. <i>Hypertension</i> , <b>2021</b> , 78, 1719-1726	8.5	4
62	Prevalence and Risk Factors for Preprocedural Medication Errors in Patients With Atrial Fibrillation and Atrial Flutter. <i>Cardiology Research</i> , <b>2021</b> , 12, 265-268	1.8	
61	Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	5
60	Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1312-1317	5.5	
59	Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 1072-1078	7.3	1
58	The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 163	4.2	1
57	Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation.. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 2372-2374	27.4	1
56	Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1777-1785	5	8
55	Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 217, 108252	4.9	5
54	Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1614-1616	27.4	13
53	Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. <i>Circulation</i> , <b>2020</b> , 142, 203-213	16.7	8
52	Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 899-908	16.2	27

51	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2354-2364	59.2	9
50	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. <i>Circulation</i> , <b>2020</b> , 141, 1214-1224	16.7	69
49	Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. <i>PLoS ONE</i> , <b>2020</b> , 15, e0222801	3.7	2
48	Generalizability of Clinical Trials Supporting the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 795-797	11.5	7
47	Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244379	3.7	1
46	Evaluation of a Health Information Technology-Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e13835	2	1
45	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 1-10	7.3	12
44	Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". <i>Circulation</i> , <b>2020</b> , 142, e212-e213	16.7	1
43	Association of Homelessness with Hospital Readmissions-an Analysis of Three Large States. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 2576-2583	4	8
42	Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 1696-1699	11.5	5
41	Cost-Effectiveness of Screening Ultrasound after a First, Febrile Urinary Tract Infection in Children Age 2-24 Months. <i>Journal of Pediatrics</i> , <b>2020</b> , 216, 73-81.e1	3.6	2
40	Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 969-977	16.2	11
39	Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e1346-e1358	13.6	15
38	Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1084-1091	16.2	63
37	Association of Medicaid Expansion With Cardiovascular Mortality. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 671-679	16.2	56
36	Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. <i>BMJ Open</i> , <b>2019</b> , 9, e027432	3	15
35	Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 828-830	16.2	26
34	Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker@ desk to the patient@ bedside. <i>Progress in Cardiovascular Diseases</i> , <b>2019</b> , 62, 406-413	8.5	6

33	PrEParing to End the HIV Epidemic - California Route as a Road Map for the United States. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2489-2491	59.2	16
32	Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 221-229	8	34
31	Using Mobile Health Intervention to Improve Secondary Prevention of Coronary Heart Diseases in China: Mixed-Methods Feasibility Study. <i>JMIR MHealth and UHealth</i> , <b>2018</b> , 6, e9	5.5	12
30	1788. Cost-Effectiveness of Penicillin Skin Testing Among Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S506-S507	1	78
29	Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data. <i>JAMA Network Open</i> , <b>2018</b> , 1, e185097	10.4	41
28	Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. <i>BMJ, The</i> , <b>2018</b> , 363, k5094	5.9	56
27	Medicare Part D Plans Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 585-588	11.5	15
26	Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. <i>Medical Clinics of North America</i> , <b>2017</b> , 101, 689-699	7	31
25	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 748-750	27.4	94
24	Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1164-1166	16.2	14
23	PCSK9 Inhibitors: Economics and Policy. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2677-2687	3.1	80
22	Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. <i>Circulation</i> , <b>2017</b> , 136, 1087-1098	16.7	56
21	Using mobile technology to optimize disease surveillance and healthcare delivery at mass gatherings: a case study from India Kumbh Mela. <i>Journal of Public Health</i> , <b>2017</b> , 39, 616-624	3.5	12
20	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 743-53	27.4	232
19	Public health aspects of the world largest mass gathering: The 2013 Kumbh Mela in Allahabad, India. <i>Journal of Public Health Policy</i> , <b>2016</b> , 37, 411-427	2.9	12
18	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 107-8	11.5	37
17	Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 88, 1017-1024	2.7	26
16	Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 2152	27.4	2

15	Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 635-42	11.5	45
14	Development of a mobile phone-based intervention to improve adherence to secondary prevention of coronary heart disease in China. <i>Journal of Medical Engineering and Technology</i> , <b>2016</b> , 40, 372-382	1.8	11
13	Thresholds for the cost-effectiveness of interventions: alternative approaches. <i>Bulletin of the World Health Organization</i> , <b>2015</b> , 93, 118-24	8.2	460
12	Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 1147-55	4	20
11	Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1411-20	15.1	63
10	The value of pharmacogenetic testingReply. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 314-5	11.5	
9	Infective endocarditis and antibiotic prophylaxis. <i>Lancet, The</i> , <b>2015</b> , 386, 530	40	2
8	Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. <i>Global Heart</i> , <b>2015</b> , 10, 111-22	2.9	73
7	Blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 247-52	15.1	79
6	Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2249-57	15.1	20
5	Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 221-32	8	61
4	Warfarin, genes, and the (health care) environment. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1338-9	11.5	3
3	The economics of heart failure. <i>Heart Failure Clinics</i> , <b>2013</b> , 9, 93-106	3.3	16
2	Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 1-14, v	2.5	19
1	Decline in Emergent and Urgent Care during the COVID-19 Pandemic		6